Plant-Based Vaccines, Antibodies & Biologics

5-7 June 2013, University of Verona, Italy

  • Increase font size
  • Default font size
  • Decrease font size

Introduction

Commercial protein drugs, which include recombinant monoclonal antibodies, subunit vaccines, immune modulators, and human enzymes, will likely exceed $100billion in market size within the next two years. A component of this extraordinary growth is the availability of new technologies to speed the time to market of new biologics, and to create improved versions of existing drugs. Among the new developments is the emerging use of green plants for recombinant protein production due to advantages over yeast, cultured mammalian or insect cells, or other living systems. It is becoming increasingly evident that:

  • Government regulatory agencies have accepted plant production in new drug approval and licensure
  • Monoclonal antibody production in plants offers rapid production advantages in comparison to mammalian cells, with at least equivalent product safety, purity and potency
  • Metabolic engineering of tobacco as a host for protein production is advancing rapidly to allow highly uniform drug products, including post-translational modifications similar to those of human cells
  • Plant-based manufacturing platforms hold major promise for next generation biogenerics (or biobetters with improved pharmacokinetic properties)
  • Plant-made subunit vaccines are in the pipeline for multiple infectious diseases
  • Ongoing corporate drug development at commercial scale is providing data to accurately determine the potential to reduce manufacturing cost of protein drugs under cGMP requirements using plant protein expression as the starting point

PBVA 2013 is the fifth meeting in this important and successful series. PBVA 2013 will offer an international forum to review the current state of research in plant protein expression systems, down-stream processing technology, the pipeline of products now in development (including vaccines, monoclonal antibodies, and human enzymes), and efforts in using these technologies in areas beyond human health (including disease prevention in animals and aquaculture).

PBVA 2013 will aim to attract an international audience of researchers, clinicians, and representatives for academia, industry and government/regulatory/public health organizations. Representatives for the human, veterinary, plant communities with an interest in vaccinology, immunology, biotechnology issues in relation to plant-based systems will find PBVA 2013 of value. PBVA 2013 will seek to develop the synergy between the human and veterinary medical/immunological/plant biotechnology communities by focusing on the immunology, vaccinology, delivery, adjuvants, and efficacy of plant based proteins.

Scientific Advisory Panel

Conference Chairman: Julian Ma (St. George’s University of London, London, UK)
Local Organizer: Mario Pezzotti (University of Verona, Italy)

Charles Arntzen (Arizona State University, USA)
George Lomonossoff (John Innes Centre, Norwich, UK)
Kevin Whaley (Mapp Biopharmaceutical Inc., USA)
Ralph Bock (MPI/MPP, Potsdam-Golm, Germany)
Rainer Fischer (RWTH Aachen, Germany)
Maurice Moloney (BBSRC Rothamsted Research, UK)
Pascal Drake (St. George’s University of London, London, UK)
Ed Rybicki (University of Capetown, South Africa)
Sun Lee (Nexgen Biotechnologies Inc., Seoul, Korea)
Yuri Gleba (Icon Genetics GmbH, Halle, Germany)
Hugh Haydon (Kentucky BioProcessing, Owensboro, Kentucky, USA)
Jim Larrick (Panorama Research Inc., USA)
Scott Deeter (Ventria Bioscience, Fort Collins, Colorado, USA)
Marc-Andre D’Aoust (Medicago Inc., Quebec, Canada)
Andres Wigdorovitz (INTA, Buenos Aires, Argentina)

 

PBVA 2013 Venue & Hotel Map

PBVA 2013 Venue & Hotel Map

PBVA 2013 Delegates

Login details will be supplied after you have registered for the event.


PBVA 2013 Sponsors

  • DNA Vaccine
  • Retroscreen Virology
  • Molecular Farming
  • iBioPharma
  • DSM
  • Kentucky Bioprocessing
  • Synthon
  • Plant Transformation Technologies
  • Protalix Biotherapeutics
  • NexGen
  • EPSO
  • Greenovation
  • ILVO
  • Fraunhofer USA
  • Icon Genetics
  • Intrucept Biomedicine
  • Nomad Biosciences
  • Medicago
  • BioVaxx
  • Mapp Biopharmaceutical
  • Aldevron
  • Fraunhofer IME
  • John Innes Centre
  • Ventria Bioscience
  • Angany Genetics
  • Root Lines Technology

PBVA 2013 Downloads

PBVA 2013 Leaflet

PBVA 2013 Mailing List

Name
E-mail Address
What is 1+4-2?